Abstract

The invention relates to a double wall lance for injecting reducing agent and oxygen through a tuyere comprising: a. an inner tube (5) for injecting reducing agent (2), b. an outer tube (6) for injecting oxygen (3) which surrounds the inner tube (5), c. an end part (7, 7a,7b,7c) closing the lance (1) and having: - a front face (11a,11b,11c) having a diameter D and comprising: i. a reducing agent outlet hole (8a,8b,8c), ii. a front face periphery (9a,9b,9c) comprising a plurality of main oxygen outlet holes (10a,10b,10c), - a cap (12a,12b,12c) surrounding the end part (7,7a,7b,7c) and extending over a length L starting from the front face (11a,11b,11c) of the end part (7, 7a,7b,7c) to a free end edge (14a,14b,14c), wherein the length L of the cap (12a,12b,12c) represents more than 21,3% of the diameter D of the front face (11a,11b,11c). The invention also relates to a method to inject hot reducing gas into a blast furnace through a tuyere (4) using such double wall lance.

IPC Classes  ?

• C21B 7/16 - Tuyères
• F27B 1/16 - Arrangements of tuyères
• F27D 3/16 - Introducing a fluid jet or current into the charge

Abstract

The present invention relates to a method for recycling concrete waste from construction and/or deconstruction, comprising at least one step of microwave processing of concrete blocks, at least one step of mechanical processing, and optionally at least one step of carbonation of the concrete fines and the recycled concrete aggregates obtained by the steps of microwave processing of concrete blocks and mechanical processing.

IPC Classes  ?

• B09B 3/50 - Destroying solid waste or transforming solid waste into something useful or harmless involving radiation, e.g. electro-magnetic waves
• C04B 20/02 - Treatment
• C04B 18/16 - Waste materialsRefuse from building or ceramic industry
• B09B 101/45 - Concrete

Abstract

6103n322n22n2n22n22nn2n2n2n2n+1n2166)alkyl.

IPC Classes  ?

• C07D 207/323 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
• C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
• C07C 67/28 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
• C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07B 31/00 - Reduction in general
• C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen
• C07C 17/361 - Preparation of halogenated hydrocarbons by reactions involving a decrease in the number of carbon atoms
• C07C 67/317 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groupsPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenolysis of functional groups

Abstract

6103n322n22n222n22nn2n2n2n2n+1n2166)alkyl.

IPC Classes  ?

• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 277/74 - Sulfur atoms substituted by carbon atoms
• C07D 277/82 - Nitrogen atoms

Abstract

222 with a compound RH, R being a hydrocarbon group, comprising optionally at least one heteroatom, for obtaining a compound having the formula R-C(=S)-F.

IPC Classes  ?

• C07C 329/04 - Esters of monothiocarbonic acids
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• C01B 32/70 - Compounds containing carbon and sulfur, e.g. thiophosgene
• C07C 333/08 - Monothiocarbamic acidsDerivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

Aortic valve stenosis (AS) also called also called Calcific aortic valve disease (CAVD), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that EZH2 inhibition with GSK-126 and GSK-343 directly regulates monocyte and M1 toward M2 macrophage differentiation, reducing VIC deactivation and osteoblastic transition and thus represents an attractive therapeutic target to prevent AS progression. Therefore, the present invention relates to use of EZH2 inhibitors for the treatment of aortic valve stenosis.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61F 2/24 - Heart valves
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to the use of an acid whey to stimulate the germination of a plant pollen grain and/or to stimulate the elongation of the pollen tube of said pollen grain. According to another aspect, the invention relates to a method for stimulating the germination of a plant pollen grain and/or for stimulating the elongation of the pollen tube of said pollen grain, in which an acid whey is applied to the plant in an amount sufficient to stimulate the germination of the pollen grain and/or to stimulate the elongation of the pollen tube of said pollen grain. According to a final aspect, the invention relates to a composition comprising (i) an acid whey and (ii) a brown seaweed extract.

IPC Classes  ?

• A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom
• A01P 21/00 - Plant growth regulators

Abstract

The invention relates to a measurement system (10) comprising: - a spectrometry device (12) comprising an ionisation source (14), a separation module (16) and a detector (18) capable of measuring an ion flow from the sample, the spectrometry device (12) being an ion cyclotron resonance mass spectrometer; and - an electronic device (20) for classifying a set of products among a plurality of classes, the device comprising a module (22) for acquiring a respective mass spectrum for each of the products of the set; a module (24) for determining, from each mass spectrum, a group of one or more compounds included in the product associated with the respective mass spectrum; a module (26) for generating a table comprising, for each of the products of the set, a value of the intensity of the ion flow for each compound present in the product; a module (28) for assigning, to each product of the set, a respective class from among the plurality of classes by applying a multivariate statistical algorithm to the generated table.

IPC Classes  ?

• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 33/28 - Oils

Abstract

The present invention relates to a compound of formula (I) or (I'): A-X (I) A-L-B (I') wherein A and B are each independently a radical of the following formula (II) : The present invention also relates to the use of a compound of formula (I) or (I') as a colouring agent, in particular as a red colouring agent. The present invention also relates to a cosmetic, a pharmaceutical composition or a food product comprising at least one compound of formula (I) or (I').

IPC Classes  ?

• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups

Abstract

The present invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/10 - Antimycotics
• A61P 35/00 - Antineoplastic agents
• C07K 5/08 - Tripeptides
• C07K 5/10 - Tetrapeptides
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

Co-signaling immunotherapy, via immune checkpoint inhibitors (ICIs), such as ipilimumab (anti-CTLA-4) or nivolumab (anti-PD-1), has revolutionized cancer treatment. However, reinvigorating tumor-infiltrating T cell cytotoxicity has revealed cardiac toxicity in a subset of patients. The inventors found lower transcriptomic expression of CTLA-4 in eccentric hypertrophic cardiomyopathy model, associated with higher cardiac total IgG amount and less B cell infiltration, compared to concentric hypertrophic cardiomyopathy. The present invention relates to a method of treating dilated cardiomyopathy (DCM) in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) molecule.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease affecting 1 in 1,000 to 1 in 2,500 individuals worldwide. The inventor's study performed in 6 patients with ADPKD supports the hypothesis that the stimulation of the dopaminergic system, in particular D1-like family of dopamine receptors, may improve endothelial function by restoring cilia length and mechanotransductory capacity. The inventors carefully assess whether the deficiency in endothelial polycystin-1 and cilia promotes or potentiates both cardiovascular and renal alterations, to explore the mechanisms involved, and to propose and test new pharmacological approaches, in particular targeting the dopaminergic system, to prevent complications of ADPKD. The present invention relates to a method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a D1-like family of dopamine receptors agonist through a continuous systemic delivery.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention relates to a method for recycling concrete waste from construction and/or deconstruction, comprising at least one step of microwave processing of concrete blocks, at least one step of mechanical processing, and at least one step of carbonation of recycled concrete aggregates and/or recycled concrete fines; the invention also relates to a recycling installation for carrying out the recycling method and to recycled concrete aggregates obtained by the steps of microwave processing of concrete blocks and mechanical processing.

IPC Classes  ?

• C04B 20/02 - Treatment

Abstract

Exacerbation of heart failure, better known as acute decompensated heart failure (HF), is characterized by dyspnea, edema and fatigue, and is a growing medical problem. The inventors demonstrated that transient O-GlcNAcase inhibition would be suitable for the treatment of acute decompensated heart failure. In particular they used two recently developed models mimicking acute decompensation of heart failure patients, and deciphered mechanisms susceptible to be involved in this cardiovascular protection, with a focus on post-translational cardiac protein modifications and metabolic remodeling. Accordingly, the present invention relates to the use of O-GlcNAcase inhibitors for the treatment of acute decompensated heart failure.

IPC Classes  ?

• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

Aortic valve stenosis (AS), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that endothelin receptor type B (ETB) activation with an agonist decreased the calcium content of VIC. Therefore, the present invention relates to the use of endothelin receptor type B (ETB) agonists for the treatment of aortic valve stenosis.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61F 2/24 - Heart valves
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Phaeodactylum tricornutumPhaeodactylum tricornutum, as well as optimized culture conditions of said microalgae cells. Altogether, the present invention provides new systems for producing high amounts of monoclonal antibodies, functional fragments or derivatives thereof, in microalgae.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The present invention relates to the field of glycerophospholipids (GPL) usable for biological studies. In particular, the invention relates to novel GPL compounds comprising at least one reactive function not interfering with the biological processes, to their process of preparation and to their uses in different applications.

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 49/00 - Preparations for testing in vivo
• C07F 9/6518 - Five-membered rings
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• C07F 9/117 - Esters of phosphoric acids with cycloaliphatic alcohols
• C07F 9/09 - Esters of phosphoric acids
• C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms

Abstract

Compounds are used in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of intoxication with at least one organophosphorus nerve agent. Pharmaceutical compositions and kits include the compounds, and compounds per se.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/695 - Silicon compounds
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine

Abstract

The invention concerns a method and a device for retrieving, from an object A, elements G present in a matrix M, characterized in that it comprises at least the following steps: bringing said abject A into contact with a dense fluid Fd with a molar mass greater than 2 g mol−1 under temperature T1 and pressure P1 conditions suitable for transforming the intergranular phase and for releasing the elements G, (302), modifying the temperature T2 and/or pressure P2 values to stop the reaction transforming the intergranular phase, (303), and recovering the elements G separated front the matrix M (304).

IPC Classes  ?

• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 59/00 - Obtaining rare earth metals
• H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets
• B01D 11/02 - Solvent extraction of solids
• B09B 3/80 - Destroying solid waste or transforming solid waste into something useful or harmless involving an extraction step
• H01F 1/057 - Alloys characterised by their composition containing rare earth metals and magnetic transition metals, e.g. SmCo5 and IIIa elements, e.g. Nd2Fe14B

Abstract

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26-32 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an 15 Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2′, N, PL-Pro). More particularly, the inventors show that detection and titration of anti-SARS-CoV-2 Spike S1 IgG and IgM antibodies are feasible by said method.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Cardiopulmonary by-pass (CBP) during cardiac surgery leads to deleterious systemic inflammatory response. In a prospective cohort of 46 patients older than 18 years and eligible for non-urgent cardiac surgery with CPB, measurement of sTREM-1 in the plasma was performed immediately after the onset of anesthesia (H0) and 2 and 24 hours after CBP. After CBP, sTREM-1 significantly increased at H2 and at H24 (p<0.001). Based on both baseline sTREM-1 levels and variations, 3 patterns of patients were identified. Profile 1 group with high baseline sTREM-1 levels as well as high increase, developed more severe organ failure after CBP with higher norepinephrine dose at H24, higher SOFA score and more frequently AKI at both H24 and H48. Finally, acute atrial fibrillation at H24 was more frequent in profile 1 when compared to profile 2/3. Profile 1 group had longer ICU and hospital length of stay (LOS). In conclusion, early sTREM-1 variations after cardiac surgery identified a group of patients at high risk for post-operative AKI and prolonged length of stay. Thus sTREM-1 represents a relevant biomarker and biotarget in cardiac surgery with CBP.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The gut microbiota produces a wide variety of metabolites, which interact with intestinal cells by modulating either gene transcription or post-translational modifications of gut proteins. The effect of gut commensal bacteria on SUMOylation, an essential ubiquitin-like modification in intestinal physiology, remains however unknown. Here, the inventors show that branched chain fatty acids (BCFAs) increase protein SUMOylation in different intestinal cell lines. They demonstrated that the hyperSUMOylation induced by BCFAs inhibits the activation of the NF-κB pathway by blocking the degradation of the inhibitory factor ΙκBα in response to TNFα. This results in a decrease in pro-inflammatory cytokines expression as well as a decrease in intestinal epithelial permeability in response to TNFα. Accordingly, the present invention relates to the use of Branched Chain Fatty Acids (BCFAs) for the treatment of diseases associated with intestinal inflammation such as Inflammatory Bowel Diseases and Irritable Bowel Syndrome.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

Aortic valve stenosis (AS) also called also called Calcific aortic valve disease (CAVD), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that EZH2 inhibition with GSK-126 and GSK-343 directly regulates monocyte and Ml toward M2 macrophage differentiation, reducing VIC deactivation and osteoblastic transition and thus represents an attractive therapeutic target to prevent AS progression. Therefore, the present invention relates to use of EZH2 inhibitors for the treatment of aortic valve stenosis.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61F 2/02 - Prostheses implantable into the body
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention is in the field of the extraction of lithium from a material comprising lithium and at least another metal. In particular, the invention concerns a process of extraction of lithium at least, from a material comprising lithium and at least another metal.

IPC Classes  ?

• C22B 26/12 - Obtaining lithium
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions

Abstract

The invention relates to the use of an acid whey to stimulate the germination of a plant pollen grain and/or to stimulate the elongation of the pollen tube of said pollen grain. According to another aspect, the invention relates to a method for stimulating the germination of a plant pollen grain and/or for stimulating the elongation of the pollen tube of said pollen grain, in which an acid whey is applied to the plant in an amount sufficient to stimulate the germination of the pollen grain and/or to stimulate the elongation of the pollen tube of said pollen grain. According to a final aspect, the invention relates to a composition comprising (i) an acid whey and (ii) a brown seaweed extract.

IPC Classes  ?

• A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom
• A01P 21/00 - Plant growth regulators

Abstract

The invention relates to the use of an acid whey to stimulate the germination of a plant pollen grain and/or to stimulate the elongation of the pollen tube of said pollen grain. According to another aspect, the invention relates to a method for stimulating the germination of a plant pollen grain and/or for stimulating the elongation of the pollen tube of said pollen grain, in which an acid whey is applied to the plant in an amount sufficient to stimulate the germination of the pollen grain and/or to stimulate the elongation of the pollen tube of said pollen grain. According to a final aspect, the invention relates to a composition comprising (i) an acid whey and (ii) a brown seaweed extract.

IPC Classes  ?

• A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom

Abstract

The invention relates to compounds of Formula I: The invention relates to compounds of Formula I: The invention relates to compounds of Formula I: or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, in particular cystic fibrosis.

IPC Classes  ?

• C07D 237/14 - Oxygen atoms
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

This invention concerns a compound having the following formula (I): This invention concerns a compound having the following formula (I): wherein either R1 is a —Y-Nu group and R2 is H, or R1 is H and R2 is a —Y-Nu group and H, wherein Y is, inter alia, —O—(CH2)m—, and m is 1, 2, or 3.

IPC Classes  ?

• C08L 5/16 - CyclodextrinDerivatives thereof
• C11D 3/22 - Carbohydrates or derivatives thereof

Abstract

The present invention relates to a method for in-vitro production of mammalian neurons expressing the 6 isoforms of the Tau protein (2N4R, 1N4R, 0N4R, 2N3R, 1N3R, 0N3R), comprising a step of neuronal differentiation, in which cellular microcompartments are cultivated for a period of 5 weeks to 100 weeks, each one comprising a hollow hydro gel capsule surrounding post-mitotic neuronal cells and an extracellular matrix, the neuronal differentiation step being carried out in a bioreactor, the cellular microcompartments being kept in suspension in an enclosure of the bioreactor containing a neuronal differentiation medium.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

The present invention relates to a method for modifying a textile yarn or fabric by immobilising a cyclodextrin derivative on said yarn or fabric, said process comprising a step (a) of contacting said textile yarn or fabric with said cyclodextrin derivative and with a bridging agent such as 1,2,3,4-butanetetracarboxylic acid, optionally in the presence of a catalyst such as cyanamide, The present invention relates to a method for modifying a textile yarn or fabric by immobilising a cyclodextrin derivative on said yarn or fabric, said process comprising a step (a) of contacting said textile yarn or fabric with said cyclodextrin derivative and with a bridging agent such as 1,2,3,4-butanetetracarboxylic acid, optionally in the presence of a catalyst such as cyanamide, to obtain a textile yarn or fabric on which the cyclodextrin derivative of formula (I) is immobilised.

IPC Classes  ?

• A62D 3/33 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by chemically fixing the harmful substance, e.g. by chelation or complexation
• D06M 15/03 - Polysaccharides or derivatives thereof

Abstract

121232322-O-], where Ar is selected from 1,4- disubstituted benzene, 4,4'- disubstituted 1,1'- biphenyl and 4,4'- disubstituted phenoxybenzene. These copolymers are particularly suited for forming stationary phases for gas chromatography, especially high-temperature gas chromatography.

IPC Classes  ?

• C08G 77/06 - Preparatory processes
• C08G 77/16 - Polysiloxanes containing silicon bound to oxygen-containing groups to hydroxy groups
• C08G 77/20 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups
• C08G 77/26 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen nitrogen-containing groups
• C08G 77/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon
• C09D 183/08 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen

Abstract

The instant invention relates to a method for labeling endonuclease-treated cells, comprising the steps of a) providing cells or a composition comprising cells; b) bringing into contact said cells or said composition with: —at least one endonuclease suitable for targeting a genomic region of interest in said cells, or a vector suitable for expressing said endonuclease in said cells; —at least one first nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), and optionally one or more non-silent mutation(s); and —at least one second nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), but distinct from the silent mutations of the first nucleic acid; thereby labeling endonuclease-treated cells.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6816 - Hybridisation assays characterised by the detection means

Abstract

The invention concerns a method for diagnosing a cancer in a subject, comprising a step of RT-MLPA on a biological sample obtained from the subject, in which the RT-MLPA step is carried out using at least one pair of probes comprising at least one probe chosen among the probes with SEQ ID NO: 1 to 13, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 866 to 938, and/or the probes with SEQ ID NO: 940 to 1104, and/or SEQ ID NO: 211 to 1312, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 1105 to 1107 and/or the probe with SEQ ID NO: 939 and/or the probes with SEQ ID NO: 1108 to 1123, each of the probes being fused, at at least one end, with a priming sequence, and at least one of the probes of the pair comprising a molecular barcode sequence.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Glossomastix Glossomastix as a texturizing agent.

IPC Classes  ?

• A61K 8/9706 - Algae
• A61Q 5/00 - Preparations for care of the hair
• A61Q 19/00 - Preparations for care of the skin
• A61K 8/9711 - Phaeophycota or Phaeophyta [brown algae], e.g. Fucus

Abstract

The present application relates to novel depolymerized exopolysaccharides derived from microalgae, the method for obtaining same from microalgae, and their use for increasing the production of collagen and/or hyaluronic acid, in order to delay the effects of skin ageing.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• A61K 8/73 - Polysaccharides
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12R 1/89 - Algae

Abstract

A tomographic atom probe includes an analysis chamber intended to analyze a sample of material in the form of a nanotip mounted on an anti-vibration support, the nanotip being brought to a temperature of between 0 kelvin and ambient temperature, the nanotip being biased at an adjustable voltage of between 1 kV and 15 kV, the analysis chamber comprising a position-sensitive and time of flight-sensitive ion detector. The atom probe comprises a generator for generating high-peak-intensity single-cycle ultrashort terahertz pulses, the analysis chamber comprising optical means for focusing the terahertz pulses, the focusing of the terahertz pulses causing the atoms of the nanotip to evaporate through the field effect without thermal effects. The terahertz pulses are generated by a femtosecond pulsed laser emitting very high-power ultrashort optical pulses at a high rate.

IPC Classes  ?

• H01J 37/285 - Emission microscopes, e.g. field-emission microscopes
• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
• H01J 37/26 - Electron or ion microscopesElectron- or ion-diffraction tubes

Abstract

The present invention relates to a natriuretic peptide selected from the group made up of (i) osteocrin, an osteocrin propeptide of osteocrin derivative, (ii) a lebetin, a lebetin fragment, or a lebetin or lebetin fragment derivative, and (iii) an ANP peptide, ANP propeptide or ANP peptide derivative, for the use thereof in a method for therapeutically treating a bacterial infection associated with a bacterial biofilm in a subject, wherein said natriuretic peptide disperses the bacterial biofilm. In a particular embodiment, the natriuretic peptide is used in combination with an antibiotic.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 38/12 - Cyclic peptides
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A01N 63/50 - Isolated enzymesIsolated proteins
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61P 31/04 - Antibacterial agents

Abstract

An accurate gene expression based classifier, and the associated assay, which can participate to the establishment a lymphoma diagnosis and to the evaluation of individual prognosis markers are provided. Through its use, one may distinguish subtypes of lymphomas such as ABC DLBCL, GCB DLBCL, PMBL, FL, MCL, SLL and MZL from one another.

IPC Classes  ?

• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/20 - Supervised data analysis

Abstract

A method for imaging a material to atomic scale by means of a field-ion microscope having a vacuum chamber configured to accommodate the material prepared in the form of a tip and an imaging gas, and an ion detector is provided. The method includes application of a DC electrical potential (VDC) and of a pulsed electrical potential, of which the maximum pulse value is denoted Vimp, so that the tip erodes for a potential value equal to VDC+Vimp; acquisition, by the detector between at least two pulses of the pulsed potential, of series of at least two ion images of the impacts of the ions repelled by the tip onto the detector; and calculation of a quantity characteristic of a trend of the erosion of the tip based on the series of ion images acquired and the adjustment, between each series of images, of the values of VDC and of Vimp such that the quantity characteristic of the trend and the ratio VDC/Vimp remain constant.

IPC Classes  ?

• H01J 37/26 - Electron or ion microscopesElectron- or ion-diffraction tubes
• H01J 37/285 - Emission microscopes, e.g. field-emission microscopes

Abstract

Pemphigus is a group of rare autoimmune diseases that causes blistering of the skin and mucous membranes, and includes pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Patients with pemphigus have various combinations of autoantibodies to keratinocyte muscarinic acetylcholine receptor subtype M3 (CHRM3), the secretory pathway Ca 2+ /Mn 2+ -ATPase 10 isoform 1 (SPCA1), and desmocollin 3 (DSC3). However, there is still a need to characterize these autoantibodies and optimize their detection for diagnosis and disease monitoring. The inventors now developed an ALBIA for the 3 proteins and successfully detected and quantified the presence of auto-antibodies directed against each of these antigens in pemphigus patients. Furthermore, they showed that detection and quantification of anti-SPCA1 and/or anti-CHRM3 15 were also associated to a risk of relapse in the first year following the treatment using rituximab as a first-line agent. The present invention thus relates to methods for detecting the presence of said pemphigus-specific autoantibodies.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Peripheral nerve injury (PNI) is frequent and many patients suffer lifelong disabilities in severe cases. Now, the inventors tested in a facial nerve regeneration model the therapeutic effect of a short mimetic peptide, named PSELT, which derives from SELENOT, an essential thioredoxinlike selenoprotein endowed with neuroprotective and antioxidant activities. The effects observed were compared to those found after an end-to-end suture used as a gold standard treatment. In addition, PSELT was used in presence or absence of transplanted, nestin-positive boundary cap-derived stem cells (BCSC) to assess the effect of the peptide in combination with a cell therapy. The analyses revealed that PSELT-treated animals exhibit a better motor recovery in terms of protraction amplitude and velocity of vibrissae compared to control and end-sutured animals. Moreover, administration of PSELT following injury enhanced muscle innervation, axonal elongation and myelination of newly formed nerve fibers. PSELT displayed a better therapeutic effect than xenotransplantation of BCSC. When PSELT was used in the presence of BCSC, no additional beneficial effect was observed in comparison to PSELT treatment alone. Accordingly, the present invention relates to use of PSELT for the treatment of nerve injuries.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present disclosure relates to ethylene-bridged nucleic acid (ENA) compounds, which may find use in therapy and/or prophylaxis. These ENA compounds may also find use as building blocks for preparing oligonucleotides, said oligonucleotides also finding use in therapy and/or prophylaxis. These compounds may be mono- or oligonucleotide derivatives comprising at least one of the following fragment: Formula (IV), wherein R1166 alkyl moiety.

IPC Classes  ?

• C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
• C07H 19/06 - Pyrimidine radicals
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07D 493/08 - Bridged systems
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 31/12 - Antivirals

Abstract

The present invention relates to compounds for their use in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of the intoxication with at least one organophosphorus nerve agent. The invention also relates to pharmaceutical compositions and kits comprising said compounds, and compounds per se.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/425 - Thiazoles
• A61K 31/433 - Thiadiazoles
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to compounds for their use in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of the intoxication with at least one organophosphorus nerve agent. The invention also relates to pharmaceutical compositions and kits comprising said compounds, and compounds per se.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The invention relates to a method for analysing the ageing stability of a bituminous binder, comprising: • a) analysing the bituminous binder by means of negative ion mode electrospray ionisation mass spectrometry and measuring the relative abundance of oxygenated compounds and non-oxygenated compounds comprising at least one nitrogen atom; • b) carrying out accelerated ageing of the bituminous binder; • c) analysing the bituminous binder, aged according to step b), after different time periods by means of negative ion mode electrospray ionisation mass spectrometry and measuring the relative abundance of oxygenated compounds and non-oxygenated compounds comprising at least one nitrogen atom; • d) comparing the measurements of the relative abundances of oxygenated compounds and non-oxygenated compounds comprising at least one nitrogen atom obtained in step a) and in step c).

IPC Classes  ?

• G01N 33/42 - Road-making materials
• H01J 49/00 - Particle spectrometers or separator tubes
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and/or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term “cardiometabolic disease” (CMD) to encompass the many facets of this complex syndrome. The inventors assessed the role of the soluble epoxide hydrolase (she) phosphatase domain in metabolism and cardiovascular system, by generating sEH phosphatase knock-in (KI) animals (rats). They unexpectedly revealed that inhibition of the phosphatase domain of sEH improves cardiac systolic function, decreases body weight and increases insulin sensitivity. Moreover under high fat diet, the animals have a decreased body weight gain, were protected against the development of insulin resistance, hepatic steatosis and cardiac hypertrophy. Inhibition of the phosphatase domain of sEH thus represents a new pharmacological target in the treatment of cardiometabolic diseases.

IPC Classes  ?

• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Microvascular dysfunction remains a major contributor to the development of skin complications. The inventors assessed the impact of the local inhibition of soluble epoxide hydrolase (sEH), which metabolizes vasodilator and anti-inflammatory epoxyeicosanoids, on the diabetic skin microvascular dysfunction. The inventors have therefore developed some formulations of sEH inhibitors (GSK2256294 and t-AUCB) for topical administration. In particular, they show that an aqueous gel containing 400 mg/L t-AUCB dissolved in 50% dimethy lsulfo xide (DMSO) allowed a stable and continuous diffusion of t-AUCB from 2 hours after application on skin pig ears to over a period of 24 h. Compared to a control gel, the gel with t-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.

IPC Classes  ?

• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 17/00 - Drugs for dermatological disorders
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26–32 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an 15 Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2', N, PL-Pro). More particularly, the inventors show that detection and titration of anti-SARS-Cov-2 Spike S1 IgG and IgM antibodies are feasible by said method.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention is in the field of the extraction of lithium from a material comprising lithium and at least another metal. In particular, the invention concerns a process of extraction of lithium at least, from a material comprising lithium and at least another metal.

IPC Classes  ?

• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 26/12 - Obtaining lithium

Abstract

The present invention is in the field of the extraction of lithium from a material comprising lithium and at least another metal. In particular, the invention concerns a process of extraction of lithium at least, from a material comprising lithium and at least another metal.

IPC Classes  ?

• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 26/12 - Obtaining lithium
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions

Abstract

The present invention relates to a device for spectroscopic measurements, in particular X-ray diffraction (XRD), temperature-resolved second harmonic generation (TR-SHG) or infrared (IR) measurements, which prevents the formation of condensation (dew) or ice (frost) when carrying out spectroscopic measurements in sub-ambient temperature conditions and to a method of spectroscopic measurements with said device.

IPC Classes  ?

• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• G01N 23/20016 - Goniometers
• G01N 23/20033 - Sample holders or supports therefor provided with temperature control or heating means
• G01N 23/207 - Diffractometry, e.g. using a probe in a central position and one or more displaceable detectors in circumferential positions

Abstract

The invention relates to compounds of formula I (I) or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, particularly cystic fibrosis.

IPC Classes  ?

• C07D 237/14 - Oxygen atoms
• A61K 31/50 - PyridazinesHydrogenated pyridazines
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The invention relates to compounds of formula I (I) or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, particularly cystic fibrosis.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems

Abstract

The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving phosphatase

Abstract

The present invention relates to a method for modifying a yarn or a textile fabric by immobilising a cyclodextrin derivative on the yarn or fabric, the method comprising a step (a) of contacting the yarn or textile fabric with the cyclodextrin derivative and a coupling agent such as 1,2,3,4-butanetetracarboxylic acid, optionally in the presence of a catalyst such as cyanamide, in order to obtain a yarn or textile fabric on which the cyclodextrin derivative of formula (I) is immobilised.

IPC Classes  ?

• D06M 15/03 - Polysaccharides or derivatives thereof
• A62D 5/00 - Composition of materials for coverings or clothing affording protection against harmful chemical agents

Abstract

12122mm-, and m is 1, 2, or 3.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• C08L 5/16 - CyclodextrinDerivatives thereof

Abstract

The invention relates to a tomographic atom probe comprising an analysis chamber (20) intended for analysing a sample (E) of material in the form of a nanotip mounted on an anti-vibration support (21), the nanotip being brought to a temperature between 0 Kelvin and room temperature, the nanotip being polarised at an adjustable voltage between 1 kV and 15 kV, the analysis chamber comprising an ion detector (27) sensitive to position and time of flight. The atom probe according to the invention comprises a generator (10) of ultrashort monocycle terahertz pulses with high peak intensity, the analysis chamber comprising optical means (26) for focusing said terahertz pulses, the focusing of the terahertz pulses leading to the evaporation of the atoms of the nanotip by field effect without thermal effects. The terahertz pulses are generated by a femtosecond pulsed laser emitting ultrashort optical pulses of very high power at a high rate.

IPC Classes  ?

• H01J 37/285 - Emission microscopes, e.g. field-emission microscopes
• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support

Abstract

The present invention relates to a natriuretic peptide selected from the group made up of (i) osteocrin, an osteocrin propeptide or osteocrin derivative, (ii) a lebetin, a lebetin fragment, or a lebetin or lebetin fragment derivative, and (iii) an ANP peptide, ANP propeptide or ANP peptide derivative, for the use thereof in a method for therapeutically treating a bacterial infection associated with a bacterial biofilm in a subject, wherein said natriuretic peptide disperses the bacterial biofilm. In a particular embodiment, the natriuretic peptide is used in combination with an antibiotic.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
• A61P 31/04 - Antibacterial agents
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention relates to a natriuretic peptide selected from the group made up of (i) osteocrin, an osteocrin propeptide or osteocrin derivative, (ii) a lebetin, a lebetin fragment, or a lebetin or lebetin fragment derivative, and (iii) an ANP peptide, ANP propeptide or ANP peptide derivative, for the use thereof in a method for therapeutically treating a bacterial infection associated with a bacterial biofilm in a subject, wherein said natriuretic peptide disperses the bacterial biofilm. In a particular embodiment, the natriuretic peptide is used in combination with an antibiotic.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a method for in-vitro production of mammalian neurons expressing the 6 isoforms of the Tau protein (2N4R, 1N4R, 0N4R, 2N3R, 1N3R, 0N3R), comprising a step of neuronal differentiation, in which cellular microcompartments are cultivated for a period of 5 weeks to 100 weeks, each one comprising a hollow hydrogel capsule surrounding post-mitotic neuronal cells and an extracellular matrix, the neuronal differentiation step being carried out in a bioreactor, the cellular microcompartments being kept in suspension in an enclosure of the bioreactor containing a neuronal differentiation medium.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/079 - Neural cells
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

Classification of B-Cell non-Hodgkin Lymphomas An accurate gene expression based classifier, and the associated assay, which can participate to the establishment a lymphoma diagnosis and to the evaluation of individual prognosis markers are provided. Through the use of the invention, one may distinguish subtypes of lymphomas such as ABC DLBCL, GCB DLBCL, PMBL, FL, MCL, SLL and MZL from one another.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Classification of B-Cell non-Hodgkin Lymphomas An accurate gene expression based classifier, and the associated assay, which can participate to the establishment a lymphoma diagnosis and to the evaluation of individual prognosis markers are provided. Through the use of the invention, one may distinguish subtypes of lymphomas such as ABC DLBCL, GCB DLBCL, PMBL, FL, MCL, SLL and MZL from one another.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

This invention relates to compounds that are inhibitors of NGAL activity, and applications thereof.

IPC Classes  ?

• A61K 31/18 - Sulfonamides
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

DCimpDCimpDCimpDCimpimp remain constant.

IPC Classes  ?

• H01J 37/285 - Emission microscopes, e.g. field-emission microscopes
• H01J 37/26 - Electron or ion microscopesElectron- or ion-diffraction tubes

Abstract

CD4 T cell help is essential to promote robust cytotoxic T cell responses and could be harnessed to improve outcomes of cancer immunotherapy. To induce CD4+ T cell responses, the inventors have developed artificial antigen presenting cells (AAPCs) that derived from a mouse fibroblast cell line genetically modified to express a single human leukocyte antigen class II molecule (HLA-DR), the human CD80 costimulation as well as CD54 and CD58 adhesion molecules and that constitutively express an antigen (Ag) in peptide or protein forms in different compartments involved in the major histocompatibility complex class II Ag presentation pathway. In particular, the inventors show that the AAPC expressing the Ag peptide in the endoplasmic reticulum (ER) or protein at the plasma membrane were more potent than Epstein-Barr virus (EBV)-transformed B cells to present epitopes to specific CD4+ T- cells. Interestingly, AAPC targeting the Ag peptide in the ER was more efficient than peptide-pulsed AAPC or autologous APC to amplify memory Ag-specific CD4+ T cells that harbor a Th1 profile and express granzyme B. So, the AAPC system is a reliable and standardized tool to generate a high number of Ag-specific CD4+ with effector functions useful for a cancer adoptive immunotherapy. Thus, the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 37/02 - Immunomodulators

Abstract

The present invention concerns a novel method for synthesising diazirines, that may or may not be enriched in nitrogen-15, from amino acids or imines, via a one-pot synthesis method, comprising the reaction of the starting amino acid or imine with ammonia, which may or may not be enriched in nitrogen-15, and a hypervalent iodine oxidant. The present invention also relates to a method for synthesising ammonia enriched in nitrogen-15. The invention also concerns certain diazirines of formula (I) likely to be obtained by the claimed synthesis method, and also refers to the 15N2-diazirines of formula (I'). The claimed diazirines can be used in photoaffinity labelling. The 15N2-diazirines can also be used in hyperpolarisation, in particular in the medical imaging field.

IPC Classes  ?

• C07D 229/02 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings

Abstract

The present invention concerns a novel method for synthesising diazirines, that may or may not be enriched in nitrogen-15, from amino acids or imines, via a one-pot synthesis method, comprising the reaction of the starting amino acid or imine with ammonia, which may or may not be enriched in nitrogen-15, and a hypervalent iodine oxidant. The present invention also relates to a method for synthesising ammonia enriched in nitrogen-15. The invention also concerns certain diazirines of formula (I) likely to be obtained by the claimed synthesis method, and also refers to the 1522-diazirines of formula (I'). The claimed diazirines can be used in photoaffinity labelling. The 1522-diazirines can also be used in hyperpolarisation, in particular in the medical imaging field.

IPC Classes  ?

• C07D 229/02 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings

Abstract

The invention concerns a method for diagnosing a cancer in a subject, comprising a step of RT-MLPA on a biological sample obtained from the subject, in which the RT-MLPA step is carried out using at least one pair of probes comprising at least one probe chosen among the probes with SEQ ID NO: 1 to 13, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 866 to 938, and/or the probes with SEQ ID NO: 940 to 1104, and/or SEQ ID NO: 211 to 1312, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 1105 to 1107 and/or the probe with SEQ ID NO: 939 and/or the probes with SEQ ID NO: 1108 to 1123, each of the probes being fused, at at least one end, with a priming sequence, and at least one of the probes of the pair comprising a molecular barcode sequence.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention concerns a method for diagnosing a cancer in a subject, comprising a step of RT-MLPA on a biological sample obtained from the subject, in which the RT-MLPA step is carried out using at least one pair of probes comprising at least one probe chosen among the probes with SEQ ID NO: 1 to 13, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 866 to 938, and/or the probes with SEQ ID NO: 940 to 1104, and/or SEQ ID NO: 211 to 1312, and/or the probes with SEQ ID NO: 96 to 99, and/or the probes with SEQ ID NO: 1105 to 1107 and/or the probe with SEQ ID NO: 939 and/or the probes with SEQ ID NO: 1108 to 1123, each of the probes being fused, at at least one end, with a priming sequence, and at least one of the probes of the pair comprising a molecular barcode sequence.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

ttttt-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/415 - 1,2-Diazoles
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and/or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term "cardiometabolic disease" (CMD) to encompass the many facets of this complex syndrome. The inventors assessed the role of the soluble epoxide hydrolase (she) phosphatase domain in metabolism and cardiovascular system, by generating sEH phosphatase knock-in (KI) animals (rats). They unexpectedly revealed that inhibition of the phosphatase domain of sEH improves cardiac systolic function, decreases body weight and increases insulin sensitivity. Moreover under high fat diet, the animals have a decreased body weight gain, were protected against the development of insulin resistance, hepatic steatosis and cardiac hypertrophy. Inhibition of the phosphatase domain of sEH thus represents a new pharmacological target in the treatment of cardiometabolic diseases.

IPC Classes  ?

• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• A61P 3/06 - Antihyperlipidemics
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione

Abstract

A laser source for emitting a group of pulses, includes a primary laser source suitable for emitting at least one primary laser pulse; at least one interferometer suitable for forming, from the primary laser pulse, a plurality of secondary laser pulses, each interferometer comprising at least one delay line allowing two secondary laser pulses to be temporally separated, by a delay comprised between 50 ps and 10 ns; and a single-mode amplifying optical fiber intended to receive the secondary laser pulses, in order to form as output a group of spatially superposed pulses.

IPC Classes  ?

• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 3/23 - Arrangement of two or more lasers not provided for in groups , e.g. tandem arrangement of separate active media
• H01S 3/094 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light
• H01S 3/067 - Fibre lasers

Abstract

Tetramorium bicarinatum.Tetramorium bicarinatum.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

An austenitic alloy based on nickel, chromium and iron, and having a high aluminum content, intended for use at a given operating temperature (Ts) between 900° C. and 1200° C., the alloy comprising the following elements, in weight percent: chromium between 20% and 32%, nickel between 30% and 60%, aluminum between 3.5% and 6%, carbon between 0.4% and 0.7%, titanium between 0.05% and 0.3%, niobium and/or tantalum between 0.6% and 2%, an element, composed of at least one rare earth and/or hafnium, between 0.002% and 0.1%, silicon between 0 and 0.5%, manganese between 0 and 0.5%, tungsten between 0 and 2%, and iron as the balance of the elements in the alloy. The alloy has less than 1% by volume of an intermetallic B2-NiAl phase and less than 1% by volume of an alpha prime phase rich in chromium, after subjecting the alloy to an operating temperature (Ts).

IPC Classes  ?

• C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
• C22F 1/10 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
• C22C 38/44 - Ferrous alloys, e.g. steel alloys containing chromium with nickel with molybdenum or tungsten
• C22C 38/48 - Ferrous alloys, e.g. steel alloys containing chromium with nickel with niobium or tantalum
• C22C 38/50 - Ferrous alloys, e.g. steel alloys containing chromium with nickel with titanium or zirconium

Abstract

The invention relates to a placental growth factor (PlGF) as a drug for use in the prevention and/or treatment of a neurological disorder, particularly a neurodevelopmental disorder. Such disorders are particularly linked to a cortical impairment in subjects having been exposed to alcohol in utero. The present invention also relates to a pharmaceutical composition or to a product comprising PlGF for the same therapeutic uses.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 25/32 - Alcohol-abuse
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a device for spectroscopic measurements, in particular X-ray diffraction (XRD), temperature-resolved second harmonic generation (TR-SHG) or infrared (IR) measurements, which prevents the formation of condensation (dew) or ice (frost) when carrying out spectroscopic measurements in sub-ambient temperature conditions and to a method of spectroscopic measurements with said device.

IPC Classes  ?

• G01N 23/20033 - Sample holders or supports therefor provided with temperature control or heating means

Abstract

The present invention relates to a device for spectroscopic measurements, in particular X-ray diffraction (XRD), temperature-resolved second harmonic generation (TR-SHG) or infrared (IR) measurements, which prevents the formation of condensation (dew) or ice (frost) when carrying out spectroscopic measurements in sub-ambient temperature conditions and to a method of spectroscopic measurements with said device.

IPC Classes  ?

• G01N 23/20033 - Sample holders or supports therefor provided with temperature control or heating means

Abstract

Embodiments of the present disclosure relate to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).

IPC Classes  ?

• C07K 5/08 - Tripeptides
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/10 - Antimycotics
• A61P 35/00 - Antineoplastic agents
• C07K 5/10 - Tetrapeptides

Abstract

The present invention relates to an alloy structure comprising germanium (Ge) and tin (Sn), characterised in that it takes the form of a filament having a diameter of less than 200 nanometers, referred to as a nanofilament, and in that the alloy contains at least 10% tin (Sn) in atomic percent (at%); and to a method for preparing such a structure, and uses thereof.

IPC Classes  ?

• C30B 23/00 - Single-crystal growth by condensing evaporated or sublimed materials
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape

Abstract

2 values to stop the reaction transforming the intergranular phase, and recovering the elements G separated front the matrix M.

IPC Classes  ?

• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 59/00 - Obtaining rare earth metals
• H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets
• B01D 11/02 - Solvent extraction of solids
• B09B 3/80 - Destroying solid waste or transforming solid waste into something useful or harmless involving an extraction step
• H01F 1/057 - Alloys characterised by their composition containing rare earth metals and magnetic transition metals, e.g. SmCo5 and IIIa elements, e.g. Nd2Fe14B

Abstract

Autoimmune myopathy (AIM) represents a group of severe inflammatory diseases. Around 60% of patients with AIM have myositis-specific auto-antibodies (aAbs). Thus, the search for aAbs has substantially improved their diagnosis and may also inform on their prognosis, notably when there is an associated risk of cancer. Accordingly, the discovery of 10 new aAbs will help to improve the diagnosis of AIM. The present invention fulfils the need. In a cohort of 671 patients suffering from patients suffering from AIM, the inventors show that a minor percentage of them were positive for the present of MDH2 aAbs. No patient was found positive for this Ab in other autoimmune diseases. Accordingly, detection of anti-MDH2 aAbs would be suitable for the diagnosis of AIM.15

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

Myocardial infarction occurs when the blood supply to part of the heart is interrupted causing some heart cells to die. The immediate goal is to restore blood flow to the patient as quickly as possible. However, a significant delay in restoring blood flow leads to a second condition known as ischemia-reperfusion injury that can develop gradually after an ischemic event and may cause irreversible damage to tissues. Successful cardioprotection is limited by a relatively small number of therapeutic targets. The present invention fulfils this need. The inventors indeed showed that a Selenoprotein T (SelT) derived peptide, SelT43-52 (PSELT), is effective against ischemia/reperfusion (I/R) injury.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

The invention relates to methods for preventing or treating resistance to EGFR inhibitors in cancer patients. More particularly, after performing a screen for small molecules potentially capable of countering cancer resistance to EGFR TKI, inventors identified the multikinase inhibitor sorafenib, which has the property, in combination with EGFR TKI, to prevent the enrichment of tumor cells containing mutations responsible for NSCLC resistance to first and third generation EGFR TKI. These data indicate that this multikinase inhibitor can prevent resistance to several generations of EGFR TKI. These in vitro data were confirmed in an in vivo xenograft mouse model of NSCLC. Finally these data were reproduced in cancer cells using SC-1, a sorafenib analogue. Accordingly, the invention relates to a method of preventing and/or treating cancer resistance to treatment with an epidermal growth factor receptor (EGFR) inhibitor in a subject in need thereof comprising administering to the subject sorafenib drug or sorafenib analogue, alone or in combination with an EGFR inhibitor.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are methods and kits for labeling endonuclease-treated cells. The methods comprise: contacting the cells to be labelled with at least one endonuclease suitable for targeting a genomic region of interest, and first and second nucleic acids suitable for introducing one or more silent (or optionally non-silent) mutation(s) in the genomic region by homology-directed repair (HDR). The mutation(s) introduced by the first nucleic acid differ from the mutation(s) introduced by the second nucleic acid.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6816 - Hybridisation assays characterised by the detection means

Abstract

Disclosed is a method and system for recovering at least rare earth elements from within an object A consisting of at least one first rare earth portion or a mixture of rare earth elements and a second metal portion. The method includes a solvothermal treatment step that places the object in contact with a fluid for causing at least one rare earth portion and/or mixture of rare earth elements and the metal portion to oxidize in order to separate same, the value of the reaction temperature Tr is selected according to the nature of the object, the reaction following a R-M→R(X)x+M(X)y scheme, where R is the rare earth element or a mixture of rare earth elements, M is the transition metal, and (X) is a group which depends on the fluid used.

IPC Classes  ?

• C01F 17/224 - Oxides or hydroxides of lanthanides
• B09B 5/00 - Operations not covered by a single other subclass or by a single other group in this subclass
• C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless

Abstract

The inventors demonstrate that the phosphatase and hydrolase domains of soluble expoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving phosphatase
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

According to one aspect, the present description relates to a laser source for emitting a group of pulses, comprising: a primary laser source (22) that is suitable for emitting at least one primary laser pulse; at least one interferometer (24) that is suitable for forming, from said primary laser pulse, a plurality of secondary lases pulses, each interferometer comprising at least one delay line allowing two secondary laser pulses to be temporally separated by a delay comprised between 50 ps and 10 ns; and a single-mode amplifying optical fibre that is intended to receive the secondary laser pulses, in order to form, as output, a group of pulses that are spatially superposed.

IPC Classes  ?

• H01S 3/067 - Fibre lasers
• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 3/094 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light
• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• G01N 21/71 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light thermally excited
• H01S 3/23 - Arrangement of two or more lasers not provided for in groups , e.g. tandem arrangement of separate active media
• G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry

Abstract

The invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO : 1, said peptide having an amino acid sequence selected from the group consisting of: a) the sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO : 1; and b) the sequences of 3 to 39 amino acids that are at least 70% identical to said sequence in a).

IPC Classes  ?

• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO : 1, said peptide having an amino acid sequence selected from the group consisting of: a) the sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO : 1; and b) the sequences of 3 to 39 amino acids that are at least 70% identical to said sequence in a).

IPC Classes  ?

• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a placental growth factor (PlGF) to be used as a drug in the prevention and/or treatment of fetal alcohol syndrome disorders (FASD) selected from the group comprising fetal alcohol syndrome (FAS), cerebrovascular disease, and growth retardation in a subject exposed to alcohol in utero. The invention also relates to a pharmaceutical composition or a product comprising the PlGF for the same therapeutic uses.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 25/32 - Alcohol-abuse
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention concerns a method and a device for retrieving, from an object A, elements G present in a matrix M, characterised in that it comprises at least the following steps: bringing said object A into contact with a dense fluid Fd with a molar mass greater than 2 g mol-1 under temperature T1 and pressure P1 conditions suitable for transforming the intergranular phase and for releasing the elements G, (302), modifying the temperature T2 and/or pressure P2 values to stop the reaction transforming the intergranular phase, (303), and recovering the elements G separated from the matrix M (304).

IPC Classes  ?

• B01D 11/02 - Solvent extraction of solids
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 59/00 - Obtaining rare earth metals
• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Goods & Services

Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; Apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; Apparatus for recording, transmission or reproduction of sound or images; Magnetic data carriers, recording discs, optical discs; Data processing and computer apparatus; Computer software (recorded programs); Peripherals adapted for use with computers; Detectors; Electric wires; Relays, electric; Diagnostic apparatus, not for medical purposes; Smart cards [integrated circuit cards]; Material testing instruments and machines; Furniture especially made for laboratories; Laboratory equipment, namely apparatus for chromatography, electrical apparatus for monitoring clinical trials, Diagnostic apparatus, not for medical purposes; Electronic publications, downloadable; Interactive multimedia computer game programs; games software downloadable to mobile phones, tablets and other electronic mobile devices; software for use on mobile phones, tablets and other electronic mobile devices; apps featuring computer games; mobile phone apps. Education, Tuition, Tuition, Publication of texts relating to teaching, Production of training films; Publishing of computer software and management software intended for schools, universities and training centres; Publishing of computer software and databases for teaching activities, training management or administration of schools, universities and training centres, publishing of computer software for the storage, processing and transmission of data; Publishing of computer software for computer network management; Online training and educational services; Providing tutoring online (education or providing of training); Publication of texts, other than publicity texts, newspapers, periodicals and all kinds of audio and/or visual media and multimedia carriers (interactive discs, audio-digital CD-ROMs, DVDs); Publication of electronic books and journals on-line; Micropublishing; Correspondence courses, courses given as part of seminars, work placements, conferences or forums; Arranging of exhibitions for cultural or educational purposes; Arranging and conducting of colloquiums, conferences and congresses; Organisation of competitions and games (education or entertainment); Game services provided on-line from a computer network; Production of television and radio programs; television entertainment; Production of films and shows, photographic reports; Leisure services. Engineering evaluations and appraisals in the fields of science and technology; Scientific and technical research; Engineering services; Scientific laboratories; designing prototypes; Material testing; Conducting technical project studies; Scientific, technical and mechanical research; Design and development of computer hardware and software; Research and development for others; Design, installation, maintenance, updating and rental of computer software; Computer programming; Computer system analysis; Computer system design; Consultancy in the field of computers; Software as a service [SaaS]; Server hosting; Energy auditing; Publication of multimedia programs and computerisation of text, still or moving images and musical or non-musical sound for interactive or non-interactive use, namely computer programming.

Abstract

The present invention relates to method of amplifying a population of antigen-specific memory CD4+ T cells using artificial presenting cells expressing HLA class II molecules. In particular, the present invention relates to a method of amplifying a population of antigen- specific memory CD4+ T cells comprising the steps of i) providing a population of artificial antigen presenting cells consisting host cells that are genetically modified to stably express at least one MHC class II molecule along with at least one accessory molecule ii) loading the population of artificial antigen presenting cells of step i) with an amount of at least one antigen of interest and iii) coculturing the suitable population of a T cells with the population of artificial antigen presenting cells of step ii).

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to a method and system for recovering at least rare earth elements from within an object A consisting of at least one first rare earth portion or a mixture of rare earth elements and a second metal portion. The invention is characterized in that it comprises a solvothermal treatment step that places the object in contact with a fluid for causing at least one rare earth portion and/or mixture of rare earth elements and the metal portion to oxidize in order to separate same, the value of the reaction temperature Tr is selected according to the nature of the object, the reaction following a R-M→ R(X)x+M(X)y scheme, where R is the rare earth element or a mixture of rare earth elements, M is the transition metal, and (X) is a group which depends on the fluid used.

IPC Classes  ?

• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless
• B09B 5/00 - Operations not covered by a single other subclass or by a single other group in this subclass
• C01F 17/00 - Compounds of rare earth metals

Abstract

The instant invention relates to a method for labeling endonuclease-treated cells, comprising the steps of: a) providing cells or a composition comprising cells; b) bringing into contact said cells or said composition with: - at least one endonuclease suitable for targeting a genomic region of interest in said cells, or a vector suitable for expressing said endonuclease in said cells; - at least one first nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), and optionally one or more non-silent mutation(s); and - at least one second nucleic acid suitable for introducing one or more silent mutation(s) in said genomic region by homology-directed repair (HDR), but distinct from the silent mutations of the first nucleic acid; thereby labeling endonuclease-treated cells.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory disease. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R agonist.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/22 - Hormones

Abstract

The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids